BIO up +1.81% percent Today $BIO High is at 113.33 and the Low 111.14 with current volume of 86,500.
Recent News posted below.
Bio-Rad Laboratories BIO other info.
http://investorshangout.com/Bio-Rad-Laboratories-BIO-50298/
BIO Bio-Rad Laboratories Recent Headline News
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - 28 mins ago
Barrett Business Services, Inc.
RYN: 26.35 (-2.47), BIO: 112.62 (+1.57), BBSI: 23.82 (-0.46), SLXP: 97.24 (+3.37), PME: 1.25 (+0.06)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of Fiduciary Duties by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Fri Nov 07, 3:39PM CST
Rigrodsky & Long, P.A. announces that it is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO) breached their fiduciary duties to shareholders.
BIO: 112.62 (+1.57)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
BWEN: 6.50 (-0.05), AIRM: 43.39 (-0.09), CPF: 19.60 (+0.16), BIO: 112.62 (+1.57), BALT: 3.22 (-0.05)
Ryan & Maniskas, LLP Announces Investigation of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 05, 6:30PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company" (NYSE: BIO).
BIO: 112.62 (+1.57)
BIO-RAD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Bio-Rad Laboratories, Inc. Following Bribery Settlement with Securities and Exchange Commission and the U.S. Department of Justice
Business Wire - Wed Nov 05, 3:58PM CST
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. a partner at the law firm of Kahn Swick & Foti, LLC ("KSF" announces that KSF has commenced an investigation into Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 112.62 (+1.57)
Bio-Red Laboratories' (BIO) CEO Norman Schwartz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:33PM CST
BIO: 112.62 (+1.57)
Bio-Rad posts 3Q profit
Automated Insights - Tue Nov 04, 5:36PM CST
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO) on Tuesday reported net income of $11.5 million, or 39 cents per share, in its third quarter.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Tue Nov 04, 5:10PM CST
Levi & Korsinsky, LLP is investigating Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company" (NYSE:BIO) in connection with possible breaches of fiduciary duty by the Board of Directors of the Company.
BIO: 112.62 (+1.57)
Bio-Rad Laboratories (BIO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
BIO: 112.62 (+1.57)
Faruqi & Faruqi, LLP is Investigating Bio-Rad Laboratories, Inc. (BIO) on Behalf of its Shareholders
PR Newswire - Tue Nov 04, 3:48PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company" (NYSE: BIO).
BIO: 112.62 (+1.57)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Bio-Rad Laboratories, Inc. (BIO) on Behalf of Shareholders
PR Newswire - Tue Nov 04, 3:47PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. (NYSE: BIO) breached their fiduciary duties to shareholders. Bio-Rad manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets.
BIO: 112.62 (+1.57)
Bio-Rad Labs misses by $0.47, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:43PM CST
BIO: 112.62 (+1.57)
Bio-Rad Reports Third-Quarter 2014 Financial Results
Marketwired - Tue Nov 04, 3:28PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2014.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Bio-Rad settles FCPA investigation
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:46AM CST
BIO: 112.62 (+1.57)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.16), ITRI: 41.45 (+0.03), AWAY: 30.31 (+0.65), OKE: 56.37 (+0.18), HR: 26.30 (-0.21), NYMT: 8.07 (+0.03), OCLR: 1.64 (-0.02), ENPH: 10.60 (-0.63), ADEP: 8.79 (+0.44), CBSO: 30.60 (+0.19), NSTG: 12.34 (-0.33), MITT: 19.20 (+0.02), CRTO: 36.83 (+0.38), FOXA: 34.79 (+0.05), OKS: 47.91 (-0.15), JMBA: 12.60 (-0.06), IVR: 16.18 (-0.08), CSU: 23.12 (-0.18), MYGN: 32.10 (-0.70), JIVE: 6.54 (+0.10), GAS: 53.54 (-0.77), COUP: 16.00 (-0.20), NRP: 12.71 (-0.31), MOSY: 1.72 (+0.04), COHR: 57.81 (-0.60), DOX: 47.47 (-0.03), CKEC: 28.08 (-0.27), OAS: 26.26 (-0.32), PAYC: 22.70 (+0.63), PCYC: 135.05 (+1.07), AXLL: 42.94 (+0.29), NP: 58.05 (-0.19), BIRT: 3.76 (-0.05), ATVI: 20.58 (-0.34), EXAM: 37.50 (+0.50), P: 18.59 (+0.09), JAZZ: 174.10 (-0.33), PBPB: 13.67 (+0.04), EXEL: 1.79 (unch), CERS: 4.18 (+0.15), DVN: 64.05 (-0.16), FEYE: 32.26 (-0.13), CHUY: 22.71 (-0.55), FRGI: 56.01 (-0.50), GHDX: 36.50 (+0.30), PACD: 6.87 (-0.23), BIO: 112.62 (+1.57), BIOL: 2.37 (+0.06), JKHY: 60.80 (-0.09), KAR: 33.11 (-0.21), CDXS: 2.38 (-0.02), MPO: 2.97 (-0.24), FANG: 67.66 (+1.06), CORT: 3.04 (-0.07), CALD: 15.81 (-0.06)
Bio-Rad paying $55M to resolve US bribery claims
By MARCY GORDON - AP - Mon Nov 03, 4:00PM CST
WASHINGTON (AP) — Bio-Rad Laboratories Inc. has agreed to pay about $55 million to resolve U.S. authorities' allegations that it failed to prevent bribery of officials in Russia, Thailand and Vietnam and falsified records to hide the payments.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government
Marketwired - Mon Nov 03, 1:16PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced the full resolution of previously disclosed investigations by the U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) into past violations of the Foreign Corrupt Practices Act (FCPA) that occurred from 2005 to 2010 related to Thailand, Vietnam, and Russia.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Alere (ALR) Lags Q3 Earnings, Revenues; Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:40PM CDT
Alere Inc. (ALR) reported disappointing third-quarter 2014 results as both the top and the bottom line missed the Zacks Consensus Estimate by a wide margin
BIO: 112.62 (+1.57), ALR: 39.62 (+0.19), CERN: 63.20 (-0.22), ATHN: 121.53 (-1.95)
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014
Marketwired - Wed Oct 08, 5:06PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2014 on Tuesday, November 4, 2014, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Recent News posted below.
Bio-Rad Laboratories BIO other info.
http://investorshangout.com/Bio-Rad-Laboratories-BIO-50298/
BIO Bio-Rad Laboratories Recent Headline News
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - 28 mins ago
Barrett Business Services, Inc.
RYN: 26.35 (-2.47), BIO: 112.62 (+1.57), BBSI: 23.82 (-0.46), SLXP: 97.24 (+3.37), PME: 1.25 (+0.06)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of Fiduciary Duties by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Fri Nov 07, 3:39PM CST
Rigrodsky & Long, P.A. announces that it is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO) breached their fiduciary duties to shareholders. BIO: 112.62 (+1.57)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
BWEN: 6.50 (-0.05), AIRM: 43.39 (-0.09), CPF: 19.60 (+0.16), BIO: 112.62 (+1.57), BALT: 3.22 (-0.05)
Ryan & Maniskas, LLP Announces Investigation of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 05, 6:30PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO). BIO: 112.62 (+1.57)
BIO-RAD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Bio-Rad Laboratories, Inc. Following Bribery Settlement with Securities and Exchange Commission and the U.S. Department of Justice
Business Wire - Wed Nov 05, 3:58PM CST
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"
announces that KSF has commenced an investigation into Bio-Rad Laboratories, Inc. (NYSE: BIO). BIO: 112.62 (+1.57)
Bio-Red Laboratories' (BIO) CEO Norman Schwartz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:33PM CST
BIO: 112.62 (+1.57)
Bio-Rad posts 3Q profit
Automated Insights - Tue Nov 04, 5:36PM CST
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO) on Tuesday reported net income of $11.5 million, or 39 cents per share, in its third quarter.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Tue Nov 04, 5:10PM CST
Levi & Korsinsky, LLP is investigating Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE:BIO) in connection with possible breaches of fiduciary duty by the Board of Directors of the Company. BIO: 112.62 (+1.57)
Bio-Rad Laboratories (BIO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
BIO: 112.62 (+1.57)
Faruqi & Faruqi, LLP is Investigating Bio-Rad Laboratories, Inc. (BIO) on Behalf of its Shareholders
PR Newswire - Tue Nov 04, 3:48PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO). BIO: 112.62 (+1.57)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Bio-Rad Laboratories, Inc. (BIO) on Behalf of Shareholders
PR Newswire - Tue Nov 04, 3:47PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. (NYSE: BIO) breached their fiduciary duties to shareholders. Bio-Rad manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets.
BIO: 112.62 (+1.57)
Bio-Rad Labs misses by $0.47, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:43PM CST
BIO: 112.62 (+1.57)
Bio-Rad Reports Third-Quarter 2014 Financial Results
Marketwired - Tue Nov 04, 3:28PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2014. BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Bio-Rad settles FCPA investigation
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:46AM CST
BIO: 112.62 (+1.57)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.16), ITRI: 41.45 (+0.03), AWAY: 30.31 (+0.65), OKE: 56.37 (+0.18), HR: 26.30 (-0.21), NYMT: 8.07 (+0.03), OCLR: 1.64 (-0.02), ENPH: 10.60 (-0.63), ADEP: 8.79 (+0.44), CBSO: 30.60 (+0.19), NSTG: 12.34 (-0.33), MITT: 19.20 (+0.02), CRTO: 36.83 (+0.38), FOXA: 34.79 (+0.05), OKS: 47.91 (-0.15), JMBA: 12.60 (-0.06), IVR: 16.18 (-0.08), CSU: 23.12 (-0.18), MYGN: 32.10 (-0.70), JIVE: 6.54 (+0.10), GAS: 53.54 (-0.77), COUP: 16.00 (-0.20), NRP: 12.71 (-0.31), MOSY: 1.72 (+0.04), COHR: 57.81 (-0.60), DOX: 47.47 (-0.03), CKEC: 28.08 (-0.27), OAS: 26.26 (-0.32), PAYC: 22.70 (+0.63), PCYC: 135.05 (+1.07), AXLL: 42.94 (+0.29), NP: 58.05 (-0.19), BIRT: 3.76 (-0.05), ATVI: 20.58 (-0.34), EXAM: 37.50 (+0.50), P: 18.59 (+0.09), JAZZ: 174.10 (-0.33), PBPB: 13.67 (+0.04), EXEL: 1.79 (unch), CERS: 4.18 (+0.15), DVN: 64.05 (-0.16), FEYE: 32.26 (-0.13), CHUY: 22.71 (-0.55), FRGI: 56.01 (-0.50), GHDX: 36.50 (+0.30), PACD: 6.87 (-0.23), BIO: 112.62 (+1.57), BIOL: 2.37 (+0.06), JKHY: 60.80 (-0.09), KAR: 33.11 (-0.21), CDXS: 2.38 (-0.02), MPO: 2.97 (-0.24), FANG: 67.66 (+1.06), CORT: 3.04 (-0.07), CALD: 15.81 (-0.06)
Bio-Rad paying $55M to resolve US bribery claims
By MARCY GORDON - AP - Mon Nov 03, 4:00PM CST
WASHINGTON (AP) — Bio-Rad Laboratories Inc. has agreed to pay about $55 million to resolve U.S. authorities' allegations that it failed to prevent bribery of officials in Russia, Thailand and Vietnam and falsified records to hide the payments.
BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government
Marketwired - Mon Nov 03, 1:16PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced the full resolution of previously disclosed investigations by the U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) into past violations of the Foreign Corrupt Practices Act (FCPA) that occurred from 2005 to 2010 related to Thailand, Vietnam, and Russia. BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
Alere (ALR) Lags Q3 Earnings, Revenues; Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:40PM CDT
Alere Inc. (ALR) reported disappointing third-quarter 2014 results as both the top and the bottom line missed the Zacks Consensus Estimate by a wide margin
BIO: 112.62 (+1.57), ALR: 39.62 (+0.19), CERN: 63.20 (-0.22), ATHN: 121.53 (-1.95)
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014
Marketwired - Wed Oct 08, 5:06PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2014 on Tuesday, November 4, 2014, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. BIO: 112.62 (+1.57), BIO.B: 113.10 (+1.80)
